Company: VCYT
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001384101-25-000060
Chunk: 17

Company: VERACYTE, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
, plant and equipment(1,819)(2,134)Net cash (used in) provided by investing activities(51,818)2,878 Financing activitiesPayment of taxes on vested restricted stock units(9,451)(3,832)Proceeds from the exercise of common stock options and employee stock purchases2,967 2,968 Net cash used in financing activities(6,484)(864)Decrease in cash, cash equivalents and restricted cash(52,940)(6,952)Effect of foreign currency on cash, cash equivalents and restricted cash74 (108)Net decrease in cash, cash equivalents and restricted cash(52,866)(7,060)Cash, cash equivalents and restricted cash at beginning of period240,631 217,330 Cash, cash equivalents and restricted cash at end of period$187,765 $210,270 Supplementary cash flow information:Purchases of property, plant and equipment included in accounts payable and accrued liability$977 $1,754 Cash paid for tax$121 $— 

Cash, Cash Equivalents and Restricted Cash:

 March 31, 2025December 31, 2024Cash and cash equivalents$186,120 $239,087 Restricted cash1,645 1,544 Total cash, cash equivalents and restricted cash$187,765 $240,631 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Table of ContentsVERACYTE, INC.Notes to Financial Statements(unaudited)

1. Organization, Description of Business and Summary of Significant Accounting Policies

 Veracyte, Inc., or Veracyte, or the Company, is a global diagnostics company that provides clinicians with tests for patients with, or potentially facing, a cancer diagnosis. Veracyte's tests are used by clinicians for diagnostic, prognostic and treatment decisions. Veracyte was incorporated in the state of Delaware on August 15, 2006, as Calderome, Inc. Calderome, Inc. operated as an incubator until early 2008. On March 4, 2008, the Company changed its name to Veracyte, Inc. The Company’s headquarters are in South San Francisco, California, and it also has operations in San Diego, California, Austin, Texas, Marseille, France, and Haifa, Israel. The Company currently offers tests in prostate cancer (Decipher Prostate); thyroid cancer (Afirma); breast